Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date |
Reported DateTime |
Company | Symbol | Insider Relationship |
Shares Traded |
Average Price |
Total Amount |
Shares Owned |
Filing |
| 2024-08-29 Purchase |
2024-09-03 5:38 pm |
Quince Therapeutics Inc. | QNCX | Thye Dirk CEO AND CHIEF MEDICAL OFFICER |
154,500 | $0.69498 | $107,375 | 843,941 (Direct) |
View |
| 2024-08-20 Purchase |
2024-08-22 5:51 pm |
Quince Therapeutics Inc. | QNCX | Ryan Charles S. PRESIDENT |
48,387 | $0.65 | $31,452 | 122,461 (Direct) |
View |
| 2024-08-19 Purchase |
2024-08-21 6:38 pm |
Quince Therapeutics Inc. | QNCX | Hannah Brendan CHIEF BUSINESS OFFICER AND COO |
38,924 | $0.62085 | $24,166 | 296,540 (Direct) |
View |
| 2023-12-12 Purchase |
2023-12-14 6:21 pm |
Quince Therapeutics Inc. | QNCX | Lamond David Director |
67,881 | $1.0199 | $69,233 | 6,686,387 (Indirect Direct) |
View |
| 2023-12-05 Purchase |
2023-12-07 6:30 pm |
Quince Therapeutics Inc. | QNCX | Lamond David Director |
57,369 | $1.0133 | $58,134 | 4,316,215 (Indirect Direct) |
View |
| 2023-11-29 Purchase |
2023-12-01 1:38 pm |
Quince Therapeutics Inc. | QNCX | Lamond David Director |
43,134 | $0.94 | $40,546 | 4,258,846 (Indirect Direct) |
View |
| 2023-08-30 Purchase |
2023-08-31 6:42 pm |
Quince Therapeutics Inc. | QNCX | Lamond David Director |
82,052 | $1.315 | $107,898 | 4,215,712 (Indirect Direct) |
View |
| 2023-08-15 Purchase |
2023-08-17 6:08 pm |
Quince Therapeutics Inc. | QNCX | Lamond David Director |
250,000 | $1.3029 | $325,737 | 4,133,660 (Indirect Direct) |
View |
| 2023-08-10 Purchase |
2023-08-11 4:15 pm |
Quince Therapeutics Inc. | QNCX | Thye Dirk Chief Executive Officer |
88,000 | $1.26 | $110,880 | 448,911 (Direct) |
View |
| 2023-08-08 Purchase |
2023-08-09 6:23 pm |
Quince Therapeutics Inc. | QNCX | Thye Dirk Chief Executive Officer |
80,000 | $1.24 | $99,200 | 360,911 (Direct) |
View |
| 2023-08-08 Purchase |
2023-08-09 6:21 pm |
Quince Therapeutics Inc. | QNCX | Hannah Brendan Chief Business Officer |
71,762 | $1.22 | $87,550 | 201,555 (Direct) |
View |
| 2023-08-08 Purchase |
2023-08-09 6:18 pm |
Quince Therapeutics Inc. | QNCX | McLoughlin Margaret Director |
8,000 | $1.23 | $9,840 | 8,000 (Direct) |
View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date |
Reported DateTime |
Exercisable Expiration |
Company | Symnbol | Insider Relationship |
Shares Traded |
Conversion Price |
Shares Owned |
Filing |
| 2025-01-28 Option Award |
2025-02-11 5:44 pm |
N/A 2035-01-27 |
Quince Therapeutics Inc. | QNCX | Thye Dirk CEO AND CHIEF MEDICAL OFFICER |
1,200,000 | $0 | 1,200,000 (Direct) |
View |
| 2025-01-28 Option Award |
2025-02-11 5:43 pm |
N/A 2035-01-27 |
Quince Therapeutics Inc. | QNCX | Ryan Charles S. PRESIDENT |
300,000 | $0 | 300,000 (Direct) |
View |
| 2025-01-28 Option Award |
2025-02-11 5:41 pm |
N/A 2035-01-27 |
Quince Therapeutics Inc. | QNCX | Hannah Brendan CBO, COO and CCO |
450,000 | $0 | 450,000 (Direct) |
View |
| 2025-01-02 Option Award |
2025-01-08 7:33 pm |
N/A 2035-01-02 |
Quince Therapeutics Inc. | QNCX | McLoughlin Margaret Director |
31,613 | $0 | 31,613 (Direct) |
View |
| 2025-01-02 Option Award |
2025-01-08 7:32 pm |
N/A 2035-01-02 |
Quince Therapeutics Inc. | QNCX | Bray June Director |
30,282 | $0 | 30,282 (Direct) |
View |
| 2025-01-02 Option Award |
2025-01-08 7:30 pm |
N/A 2035-01-02 |
Quince Therapeutics Inc. | QNCX | Lamond David Director |
47,587 | $0 | 47,587 (Direct) |
View |
| 2025-01-02 Option Award |
2025-01-08 7:29 pm |
N/A 2035-01-02 |
Quince Therapeutics Inc. | QNCX | Senner Christopher J. Director |
35,274 | $0 | 35,274 (Direct) |
View |
| 2024-06-05 Option Award |
2024-06-07 9:08 pm |
2025-06-05 2034-06-05 |
Quince Therapeutics Inc. | QNCX | Lamond David Director |
27,000 | $0 | 27,000 (Direct) |
View |
| 2024-06-05 Option Award |
2024-06-07 9:04 pm |
2025-06-05 2034-06-05 |
Quince Therapeutics Inc. | QNCX | McLoughlin Margaret Director |
27,000 | $0 | 27,000 (Direct) |
View |
| 2024-06-05 Option Award |
2024-06-07 9:03 pm |
2025-06-05 2034-06-05 |
Quince Therapeutics Inc. | QNCX | RYAN UNA S Director |
27,000 | $0 | 27,000 (Direct) |
View |
| 2024-06-05 Option Award |
2024-06-07 9:00 pm |
2025-06-05 2034-06-05 |
Quince Therapeutics Inc. | QNCX | Senner Christopher J. Director |
27,000 | $0 | 27,000 (Direct) |
View |
| 2024-06-05 Option Award |
2024-06-07 8:59 pm |
2025-06-05 2034-06-05 |
Quince Therapeutics Inc. | QNCX | Bray June Director |
27,000 | $0 | 27,000 (Direct) |
View |
| 2024-06-05 Option Award |
2024-06-07 8:57 pm |
2025-06-05 2034-06-05 |
Quince Therapeutics Inc. | QNCX | Benatti Luca Director |
27,000 | $0 | 27,000 (Direct) |
View |
| 2024-06-05 Option Award |
2024-06-07 8:55 pm |
2025-06-05 2034-06-05 |
Quince Therapeutics Inc. | QNCX | Patni Rajiv Director |
13,500 | $0 | 13,500 (Direct) |
View |
| 2024-06-04 Exercise |
2024-06-05 2:37 pm |
N/A N/A |
Quince Therapeutics Inc. | QNCX | Hannah Brendan CHIEF BUSINESS OFFICER AND COO |
56,061 | $0.55 | 305,055 (Direct) |
View |
| 2024-06-04 Exercise |
2024-06-05 2:37 pm |
N/A 2032-03-27 |
Quince Therapeutics Inc. | QNCX | Hannah Brendan CHIEF BUSINESS OFFICER AND COO |
56,061 | $0 | 305,055 (Direct) |
View |
| 2024-02-15 Option Award |
2024-02-15 6:14 pm |
N/A 2034-02-15 |
Quince Therapeutics Inc. | QNCX | Patni Rajiv Director |
54,000 | $0 | 54,000 (Direct) |
View |
| 2024-02-01 Option Award |
2024-02-02 6:02 pm |
N/A 2034-01-31 |
Quince Therapeutics Inc. | QNCX | Ryan Charles S. PRESIDENT |
145,000 | $0 | 145,000 (Direct) |
View |
| 2024-02-01 Option Award |
2024-02-02 5:53 pm |
N/A 2034-01-31 |
Quince Therapeutics Inc. | QNCX | Hannah Brendan CHIEF BUSINESS OFFICER AND COO |
600,000 | $0 | 600,000 (Direct) |
View |
| 2024-02-01 Option Award |
2024-02-02 5:50 pm |
N/A 2034-01-31 |
Quince Therapeutics Inc. | QNCX | Thye Dirk CEO AND CHIEF MEDICAL OFFICER |
1,500,000 | $0 | 1,500,000 (Direct) |
View |
| 2024-01-16 Exercise |
2024-01-17 4:48 pm |
N/A N/A |
Quince Therapeutics Inc. | QNCX | Thye Dirk CHIEF EXECUTIVE OFFICER |
90,531 | $0.55 | 1,255,302 (Direct) |
View |
| 2024-01-16 Exercise |
2024-01-17 4:48 pm |
N/A 2022-03-27 |
Quince Therapeutics Inc. | QNCX | Thye Dirk CHIEF EXECUTIVE OFFICER |
240,530 | $0 | 1,255,302 (Direct) |
View |
| 2024-01-16 Exercise |
2024-01-17 4:48 pm |
N/A N/A |
Quince Therapeutics Inc. | QNCX | Thye Dirk CHIEF EXECUTIVE OFFICER |
149,999 | $0.94 | 1,255,302 (Direct) |
View |
| 2023-10-24 Option Award |
2023-10-26 5:54 pm |
N/A 2033-10-23 |
Quince Therapeutics Inc. | QNCX | Hannah Brendan Chief Business Officer and COO |
75,000 | $0 | 75,000 (Direct) |
View |
| 2023-10-23 Option Award |
2023-10-24 7:46 pm |
N/A 2033-10-22 |
Quince Therapeutics Inc. | QNCX | Benatti Luca Director |
54,000 | $0 | 54,000 (Direct) |
View |
Ownership |
2023-10-24 7:43 pm |
N/A N/A |
Quince Therapeutics Inc. | QNCX | Benatti Luca Director |
0 | $0 | 80,261 (Direct) |
View |
| 2023-10-23 Option Award |
2023-10-24 7:42 pm |
N/A 2033-10-22 |
Quince Therapeutics Inc. | QNCX | Janhofer Guenter Chief Scientific Officer |
300,000 | $0 | 300,000 (Direct) |
View |
Ownership |
2023-10-24 7:34 pm |
N/A N/A |
Quince Therapeutics Inc. | QNCX | Janhofer Guenter Chief Scientific Officer |
0 | $0 | 15,008 (Direct) |
View |
| 2023-09-01 Option Award |
2023-09-06 5:43 pm |
N/A 2033-08-31 |
Quince Therapeutics Inc. | QNCX | Ryan Charles S. President |
545,000 | $0 | 545,000 (Direct) |
View |
Ownership |
2023-09-06 5:40 pm |
N/A N/A |
Quince Therapeutics Inc. | QNCX | Ryan Charles S. President |
0 | $0 | 74,074 (Direct) |
View |